...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Enthusiasm? NOT!

Nextblockbuster, I think you are right and that is the one big and sad problem we face. While I was being somewhat facetious about Dicky To I do think that when ORI converted the debenture to shares the did so with their ROI objectives in their 3 to 5 year time frame. I do think they will exert help or pressure in order to get performance.

It just seems so odd that with all of the promising and proven science that neither company has any value yet other Canadian biotech have achieved amazing rewards for shareholders even with out the proven successes of RVX.

Don could make a tremendous amount of money by stepping aside. Either way he will benefit enormously no matter what happens.

GLTA

Grouchy Toinv

Share
New Message
Please login to post a reply